BioWorld MedTech

Jan. 13, 2016

J.P. Morgan Healthcare Conference 2016: Medtronic to return $5 billion of freed cash to shareholders

SAN FRANCISCO — As Medtronic plc (Dublin) approaches the anniversary of its blockbuster Covidien deal, which closed a year ago this month, the company is making strides to prove the $42.9 billion acquisition is paying off. Read More

J.P. Morgan Healthcare Conference 2016: Heartware suffers more heartache over MVAD, trial in limbo after thrombus events

Inside the Beltway: Califf breezes through Senate hearing for top job at the FDA

Company accused of lowering evidence bar: PDAC once again votes to recommend Probuphine implant

Silimed issues still not resolved: Sientra's new CEO updates physicians over crisis with Brazilian operations

Daily M&A: Smith & Nephew acquires BST-Cargel assets from Piramal Healthcare

Financings: Accuray closes $70M straight debt agreements with Cerberus

Patent Watch: Entac gets patent for technology to predict gastrointestinal impairment

World in Review: Polaris using DNAnexus for clinical omics

People in Places

product briefs

MDD's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis

BioWorld

Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...